Tumor targeting via EPR: Strategies to enhance patient responses.
暂无分享,去创建一个
Fabian Kiessling | Benjamin Theek | Twan Lammers | F. Kiessling | T. Lammers | B. Theek | Susanne K Golombek | Jan-Niklas May | Lia Appold | N. Drude | Lia Appold | Natascha Drude | Jan-Niklas May | Benjamin Theek
[1] D. Jaffray,et al. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[2] A. Witkamp,et al. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. , 2001, Cancer treatment reviews.
[3] J. Sozanski,et al. Temperature control and thermal dosimetry by microwave radiometry in hyperthermia , 1996 .
[4] A. Jimeno,et al. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] Tayyaba Hasan,et al. Tumor Vascular Permeabilization by Vascular-Targeting Photosensitization: Effects, Mechanism, and Therapeutic Implications , 2006, Clinical Cancer Research.
[6] Benjamin J Vakoc,et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging , 2009, Nature Medicine.
[7] Michael R Hamblin,et al. Scavenger-Receptor Targeted Photodynamic Therapy¶ , 2000, Photochemistry and photobiology.
[8] C. Moonen,et al. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. , 2017, Advanced drug delivery reviews.
[9] Xian-feng Ding,et al. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice , 2017, Journal of Zhejiang University-SCIENCE B.
[10] K. Hori,et al. Fluctuations in Tumor Blood Flow under Normotension and the Effect of Angiotensin II‐induced Hypertension , 1991, Japanese journal of cancer research : Gann.
[11] Hayley E. Francies,et al. Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.
[12] P. O'Connor,et al. Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models , 2010, Molecular Cancer Therapeutics.
[13] Zvi Fuks,et al. Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.
[14] Fabian Kiessling,et al. Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. , 2014, Nano letters.
[15] H. Maeda,et al. Tumor‐selective Blood Flow Decrease Induced by an Angiotensin Converting Enzyme Inhibitor, Temocapril Hydrochloride , 2000, Japanese journal of cancer research : Gann.
[16] H. Maeda,et al. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. , 2009, Japanese journal of clinical oncology.
[17] Mauro Ferrari,et al. Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. , 2014, Cancer research.
[18] Alexander L. Klibanov,et al. Microbubbles in ultrasound-triggered drug and gene delivery. , 2008, Advanced drug delivery reviews.
[19] R. Jain,et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.
[20] T. Okinaga,et al. Local delivery system of cytotoxic agents to tumors by focused sonoporation , 2007, Cancer Gene Therapy.
[21] H. Dvorak,et al. Why are tumour blood vessels abnormal and why is it important to know? , 2009, British Journal of Cancer.
[22] Rolf Bjerkvig,et al. In vivo models of primary brain tumors: pitfalls and perspectives , 2012, Neuro-oncology.
[23] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[24] B. Henderson,et al. SITES OF PHOTODAMAGE in vivo and in vitro BY A CATIONIC PORPHYRIN , 1995, Photochemistry and photobiology.
[25] S. Libutti,et al. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. , 2012, Journal of vascular and interventional radiology : JVIR.
[26] Tetsurou Yamamoto,et al. Involvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue , 1988, Japanese journal of cancer research : Gann.
[27] G. Storm,et al. Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: protein corona as a critical determinant. , 2016, Nanomedicine.
[28] Nathan McDannold,et al. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. , 2014, Advanced drug delivery reviews.
[29] D. Tarin,et al. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. , 2011, Bioconjugate chemistry.
[30] H. Dvorak. Discovery of vascular permeability factor (VPF). , 2006, Experimental cell research.
[31] M. V. van Zandvoort,et al. PBCA‐based polymeric microbubbles for molecular imaging and drug delivery , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[32] Triantafyllos Stylianopoulos,et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors , 2012, Proceedings of the National Academy of Sciences.
[33] M. May. Cancer research with a human touch , 2018, Nature.
[34] Khaled Greish,et al. Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet? , 2012, Drug discovery today. Technologies.
[35] T. Lagerweij,et al. Human pontine glioma cells can induce murine tumors , 2014, Acta Neuropathologica.
[36] F. Kiessling,et al. Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[37] V. Préat,et al. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. , 2012, Molecular pharmaceutics.
[38] C. Curtis,et al. Organoids reveal cancer dynamics , 2018, Nature.
[39] R. Jain. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] R. Muschel,et al. Drug radiotherapy combinations: review of previous failures and reasons for future optimism. , 2015, Cancer treatment reviews.
[41] Fabian Kiessling,et al. Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy , 2010 .
[42] Manuel Hidalgo,et al. Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.
[43] O. Kaidar-Person,et al. Application of nanotechnology to cancer radiotherapy , 2016, Cancer Nanotechnology.
[44] Zahi A. Fayad,et al. Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy , 2016, Nature Communications.
[45] M. Dewhirst,et al. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. , 2001, Cancer research.
[46] Wei He,et al. Core-shell nanocarriers with high paclitaxel loading for passive and active targeting , 2016, Scientific Reports.
[47] Takahiro Nomoto,et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. , 2013, ACS nano.
[48] M. Dewhirst,et al. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. , 2000, Cancer research.
[49] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Hongyu,et al. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. , 2015, ACS nano.
[51] Ralph Weissleder,et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2015, Nature Communications.
[52] Betty Y. S. Kim,et al. Lessons from immuno-oncology: a new era for cancer nanomedicine? , 2017, Nature Reviews Drug Discovery.
[53] W. Dewey,et al. Hyperthermia and radiation--a selective thermal effect on chronically hypoxic tumor cells in vivo. , 1977, International journal of radiation oncology, biology, physics.
[54] T. Hagemann,et al. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. , 2015, Cancer cell.
[55] R. Lencioni,et al. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. , 2016, Hepatic oncology.
[56] A. Molven,et al. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[57] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[58] Kinam Park. To PEGylate or not to PEGylate, that is not the question. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[59] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[60] P. Choyke,et al. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. , 2013, ACS nano.
[61] K. Hynynen,et al. Thermosensitive nanomedicines could revolutionize thermal therapy in oncology , 2017 .
[62] S. Libutti,et al. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. , 2002, Blood.
[63] G. Winter,et al. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo characterization. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[64] R. Jain,et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors , 2011, Proceedings of the National Academy of Sciences.
[65] Jian Cao,et al. Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas , 2015, Genes & diseases.
[66] M. Dewhirst,et al. Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma. , 2018, JAMA oncology.
[67] F. Danhier,et al. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[68] R. Jain,et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.
[69] K. Ulbrich,et al. Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. , 2013, Biomaterials.
[70] O. Kaalhus,et al. Radiation Improves the Distribution and Uptake of Liposomal Doxorubicin (Caelyx) in Human Osteosarcoma Xenografts , 2004, Cancer Research.
[71] Eduardo G. Moros,et al. Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the treatment of recurrent or persistent human tumors: A prospectively controlled randomized study by the radiation therapy oncology group , 1993 .
[72] Holger Gerhardt,et al. Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.
[73] David J. Waxman,et al. Multi‐modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[74] Tuan Vo-Dinh,et al. Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers , 2017, Scientific Reports.
[75] M. V. van Zandvoort,et al. Image-guided, targeted and triggered drug delivery to tumors using polymer-based microbubbles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[76] Xiaoyuan Chen,et al. Rethinking cancer nanotheranostics. , 2017, Nature reviews. Materials.
[77] M. V. van Zandvoort,et al. Theranostic USPIO‐Loaded Microbubbles for Mediating and Monitoring Blood‐Brain Barrier Permeation , 2015, Advanced functional materials.
[78] Ashish Ranjan,et al. Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[79] Miles A. Miller,et al. Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts , 2017, Science Translational Medicine.
[80] M. Dewhirst,et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. , 2012, Cancer research.
[81] M. Hidalgo,et al. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts , 2016, Molecular Cancer Therapeutics.
[82] David Kessel,et al. Photodynamic therapy of cancer: An update , 2011, CA: a cancer journal for clinicians.
[83] P. Choyke,et al. The Effect of Photoimmunotherapy Followed by Liposomal Daunorubicin in a Mixed Tumor Model: A Demonstration of the Super-Enhanced Permeability and Retention Effect after Photoimmunotherapy , 2013, Molecular Cancer Therapeutics.
[84] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[85] K. Kinzler,et al. A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles , 2011, Oncotarget.
[86] M. Bally,et al. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.
[87] R. Vile,et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[88] F. Kiessling,et al. Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[89] Y. Matsumura. Cancer stromal targeting (CAST) therapy. , 2012, Advanced drug delivery reviews.
[90] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[91] Zhijian J. Chen,et al. A STING-Activating Nanovaccine for Cancer Immunotherapy , 2017, Nature nanotechnology.
[92] Karen Campbell,et al. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer , 2017, Clinical Cancer Research.
[93] S. Noguchi,et al. Augmentation of anticancer effect with angiotensin II in intraarterial infusion chemotherapy for breast carcinoma , 1988, Cancer.
[94] D. K. Ways,et al. Effect of Ionizing Radiation on AP-1 Binding Activity and Basic Fibroblast Growth Factor Gene Expression in Drug-sensitive Human Breast Carcinoma MCF-7 and Multidrug-resistant MCF-7/ADR Cells * , 1995, The Journal of Biological Chemistry.
[95] B. Alman,et al. Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood. , 2017, ACS nano.
[96] R. Korn,et al. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study , 2017, Clinical Cancer Research.
[97] E. Voest,et al. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery. , 2017, Cell chemical biology.
[98] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[99] J. Erler,et al. Targeting ECM Disrupts Cancer Progression , 2015, Front. Oncol..
[100] F. Szoka,et al. Macrophage-based cell therapies: The long and winding road. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[101] R. Jain,et al. Solid stress generated by spheroid growth estimated using a linear poroelasticity model. , 2003, Microvascular research.
[102] E. Unanue,et al. Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. , 1991, Journal of immunology.
[103] Tracy T Batchelor,et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. , 2012, Cancer research.
[104] R. Goldberg,et al. Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): A single-institution experience. , 2015 .
[105] R K Jain,et al. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.
[106] Y. Matsumura,et al. New concept of cytotoxic immunoconjugate therapy targeting cancer‐induced fibrin clots , 2011, Cancer science.
[107] T. Hongo,et al. Angiotensin‐Induced Hypertension Chemotherapy in Children with Advanced Solid Tumors , 1991, Acta paediatrica Japonica : Overseas edition.
[108] Rakesh K. Jain,et al. Pathology: Cancer cells compress intratumour vessels , 2004, Nature.
[109] R. Jain,et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.
[110] Lei Xu,et al. Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.
[111] L Tupchong,et al. Randomized Phase III Study Comparing Irradiation and Hyperthermia with Irradiation Alone in Superficial Measurable Tumors: Final Report by the Radiation Therapy Oncology Group , 1991, American journal of clinical oncology.
[112] P Wust,et al. Simulation studies promote technological development of radiofrequency phased array hyperthermia. , 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[113] Fabian Kiessling,et al. Micro-CT Imaging of Tumor Angiogenesis Quantitative Measures Describing Micromorphology and Vascularization , 2014 .
[114] K. Ulbrich,et al. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy , 2008, British Journal of Cancer.
[115] Jeffrey A. Engelman,et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy , 2017, Nature Reviews Cancer.
[116] Kwangmeyung Kim,et al. Engineering nanoparticle strategies for effective cancer immunotherapy. , 2018, Biomaterials.
[117] Mark W Dewhirst,et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. , 2007, Journal of the National Cancer Institute.
[118] A. Deal,et al. Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models. , 2017, Nanomedicine : nanotechnology, biology, and medicine.
[119] R. Weichselbaum,et al. Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. , 2016, Journal of the American Chemical Society.
[120] F. Kiessling,et al. Recent advances in ultrasound-based diagnosis and therapy with micro- and nanometer-sized formulations. , 2017, Methods.
[121] M. Caligiuri,et al. Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever‐like) whole body hyperthermia , 1998, Journal of cellular physiology.
[122] K. Leong,et al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. , 2016, Biomaterials.
[123] Ralph R. Weichselbaum,et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy , 2016, Nature Communications.
[124] I. Hsu,et al. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer , 2014, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[125] Rakesh K. Jain,et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels , 2013, Nature Communications.
[126] G. Calais,et al. Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma. , 1999, Journal of the National Cancer Institute.
[127] Lawrence Mayer,et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. , 2009, Leukemia research.
[128] D. Ribatti,et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.
[129] Qin Xu,et al. Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy. , 2016, ACS applied materials & interfaces.
[130] R. Mertelsmann,et al. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[131] J. Verweij,et al. Renal toxicities of chemotherapy. , 2006, Seminars in Oncology.
[132] J. Isola,et al. Trastuzumab emtansine: mechanisms of action and drug resistance , 2014, Breast Cancer Research.
[133] L. Cardoso,et al. Quantification of transient increase of the blood–brain barrier permeability to macromolecules by optimized focused ultrasound combined with microbubbles , 2014, International journal of nanomedicine.
[134] Giridhar Thiagarajan,et al. Nanoparticle toxicity assessment using an in vitro 3-D kidney organoid culture model. , 2014, Biomaterials.
[135] Mark E. Davis,et al. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles , 2009, Proceedings of the National Academy of Sciences.
[136] L. Mayer,et al. Optimizing combination chemotherapy by controlling drug ratios. , 2007, Molecular interventions.
[137] A. Eggermont,et al. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.
[138] Chiara Brignole,et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. , 2006, Cancer research.
[139] Theresa M. Allen,et al. Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.
[140] Y. Barenholz,et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.
[141] R K Jain,et al. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. , 1999, Cancer research.
[142] Natalia Vykhodtseva,et al. Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. , 2012, Ultrasound in medicine & biology.
[143] K Hynynen,et al. Ultrasound technology for hyperthermia. , 1999, Ultrasound in medicine & biology.
[144] J. Kopeček,et al. Biological rationale for the design of polymeric anti-cancer nanomedicines , 2013, Journal of drug targeting.
[145] F. Kiessling,et al. Balancing Passive and Active Targeting to Different Tumor Compartments Using Riboflavin-Functionalized Polymeric Nanocarriers. , 2017, Nano letters.
[146] Horst Kessler,et al. Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation , 2010, Anti-cancer agents in medicinal chemistry.
[147] Paul Workman,et al. How Much Longer Will We Put Up With $100,000 Cancer Drugs? , 2017, Cell.
[148] F. Greco,et al. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection. , 2017, Journal of pharmaceutical sciences.
[149] Paul A. Dayton,et al. Optical observation of lipid- and polymer-shelled ultrasound microbubble contrast agents , 2004 .
[150] Jennifer I. Hare,et al. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. , 2017, Advanced drug delivery reviews.
[151] H. Maeda,et al. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. , 1993, British Journal of Cancer.
[152] K. Hakamada,et al. International Journal of Molecular Sciences the Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma , 2022 .
[153] J. Cortes,et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. , 2016 .
[154] Zhigang Wang,et al. Antitumor Effect of Docetaxel‐Loaded Lipid Microbubbles Combined With Ultrasound‐Targeted Microbubble Activation on VX2 Rabbit Liver Tumors , 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[155] A. Eggermont,et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[156] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[157] J. Folkman,et al. ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.
[158] Wen Jiang,et al. Designing nanomedicine for immuno-oncology , 2017, Nature Biomedical Engineering.
[159] Triantafyllos Stylianopoulos,et al. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. , 2011, Annual review of chemical and biomolecular engineering.
[160] Kevin J. Harrington,et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence , 2015, Nature Reviews Cancer.
[161] A. Garden,et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[162] P. Stayton,et al. Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[163] Rakesh K. Jain,et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.
[164] K. Greish,et al. Tumor Vasculature, EPR Effect, and Anticancer Nanomedicine: Connecting the Dots , 2013 .
[165] H. Maeda,et al. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.
[166] Brian Seed,et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation , 2003, Nature Medicine.
[167] Karl Deisseroth,et al. Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity , 2017, Nature Biomedical Engineering.
[168] Fabian Kiessling,et al. Cancer nanomedicine: Is targeting our target? , 2016, Nature reviews. Materials.
[169] G. Duigou,et al. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways , 2001, Oncogene.
[170] R. Jain,et al. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. , 1996, Cancer research.
[171] S. Eberhardt,et al. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[172] Vladimir Torchilin,et al. Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.
[173] R K Jain,et al. Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.
[174] A. Giatromanolaki,et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy. , 2000, Acta oncologica.
[175] G. Batist,et al. A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC) , 2008 .
[176] M. Kester,et al. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. , 2016, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[177] M. Ferrari,et al. Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. , 2017, Seminars in immunology.
[178] A. J. Tavares,et al. Analysis of nanoparticle delivery to tumours , 2016 .
[179] H. Maeda. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[180] Anang A. Shelat,et al. Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors , 2017, Nature.
[181] Rogério Gaspar,et al. Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking , 2014, Front. Chem..
[182] R. Jain,et al. Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. , 1993, Cancer research.
[183] Takashi Nakamura,et al. Integration of nano drug-delivery system with cancer immunotherapy. , 2017, Therapeutic delivery.
[184] Yechezkel Barenholz,et al. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs , 1993, Pharmaceutical Research.
[185] A. Nel,et al. New Insights into "Permeability" as in the Enhanced Permeability and Retention Effect of Cancer Nanotherapeutics. , 2017, ACS nano.
[186] Özlem Türeci,et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.
[187] Laurence Zitvogel,et al. Mouse models in oncoimmunology , 2016, Nature Reviews Cancer.
[188] U. Klingmüller,et al. Erythropoietin Improves the Accumulation and Therapeutic Effects of Carboplatin by Enhancing Tumor Vascularization and Perfusion , 2015, Theranostics.
[189] H. Verheul,et al. The Role of Vascular Endothelial Growth Factor (VEGF) in Tumor Angiogenesis and Early Clinical Development of VEGFReceptor Kinase Inhibitors , 2000 .
[190] K. Ulbrich,et al. Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[191] Bradford J. Wood,et al. Comparison of Conventional Chemotherapy, Stealth Liposomes and Temperature-Sensitive Liposomes in a Mathematical Model , 2012, PloS one.
[192] M. Amichetti,et al. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. , 1994, International journal of radiation oncology, biology, physics.
[193] M. Halyard,et al. Benefits, risks, and safety of external beam radiation therapy for breast cancer , 2015, International journal of women's health.
[194] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[195] V. Gebski,et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials , 2017, The Lancet. Oncology.
[196] P. Peschke,et al. Morphometric analysis of bromodeoxyuridine distribution and cell density in the rat Dunning prostate tumor R3327-AT1 following treatment with radiation and/or hyperthermia. , 1999, Histology and histopathology.
[197] J. Baselga,et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.
[198] Hans Clevers,et al. Intra-tumour diversification in colorectal cancer at the single-cell level , 2018, Nature.
[199] P. Schlag,et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.
[200] Khaled Greish,et al. Nanomedicine: is it lost in translation? , 2018, Therapeutic delivery.
[201] A. Dudley. Tumor endothelial cells. , 2012, Cold Spring Harbor perspectives in medicine.
[202] Lyndsay Harris,et al. Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.
[203] K. Berg,et al. THE PHOTODEGRADATION OF PORPHYRINS IN CELLS CAN BE USED TO ESTIMATE THE LIFETIME OF SINGLET OXYGEN , 1991, Photochemistry and photobiology.
[204] N. Ferrara,et al. VEGF inhibition: insights from preclinical and clinical studies , 2008, Cell and Tissue Research.
[205] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[206] J. Kolitz,et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[207] D. Kessel,et al. Mitochondrial photodamage and PDT-induced apoptosis. , 1998, Journal of photochemistry and photobiology. B, Biology.
[208] Timothy W. Secomb,et al. Transport of drugs from blood vessels to tumour tissue , 2017, Nature Reviews Cancer.
[209] E. Barbier,et al. An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors , 2016, Scientific Reports.
[210] Hiroshi Maeda,et al. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs , 2018, Clinical and Translational Medicine.
[211] H. Maeda,et al. Tumor-Targeted Macromolecular Drug Delivery Based on the Enhanced Permeability and Retention Effect in Solid Tumor , 2009 .
[212] S B Kaye,et al. On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.
[213] F. Kiessling,et al. Ultrasound-mediated drug delivery to the brain: principles, progress and prospects. , 2016, Drug discovery today. Technologies.
[214] R K Jain,et al. Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.
[215] Ashley M. Laughney,et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.
[216] Z. Duan,et al. Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model , 2008, Molecular pharmaceutics.
[217] B. Hendriks,et al. Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines , 2018, Theranostics.
[218] D. Sica,et al. Clinical Pharmacokinetics of Losartan , 2005, Clinical pharmacokinetics.